Alpha Vulture
Deep value, special situations, long-term horizon, micro-cap

PD-Rx Pharmaceuticals: Growth At A Bargain Price

Executive summary:

  • PD-Rx Pharmaceuticals available for sale at dirt cheap 2.1x EV/EBIT, 6.7x PE and 1.0x P/B multiples.
  • Exit of McKesson from the dispensing market - its biggest competitor - provides meaningful growth opportunity.
  • PD-Rx has a long history of growth, and is profitable since 1993.



Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.